Literature DB >> 185060

Receptors for immune complexes on cells within a polyoma virus-induced murine sarcoma.

G R Braslawsky, D Serban, I P Witz.   

Abstract

Cells present in the polyoma virus-induced murine ascites tumor SEYF-a showed the capacity to fix soluble immune complexes of ovalbumin anti-ovalbumin. The fixation could be inhibited by preincubating the cells with antisera directed against H-2 antigens and with syngeneic anti-tumor antibodies. The latter did not react with normal cells. Depletion of phagocytes from the ascites cell population, thus enriching for tumor cells, increased the inhibition of complex fixation by the syngeneic anti-tumor antiserum. The inhibition of complex fixation by the anti-tumor antibodies was not mediated by "third-party" complexes. Pepsin-treated globulin derived from the syngeneic anti-tumor antiserum could still inhibit complex fixation by SEYF-a cells. These results raise the possibility that tumor cells, per se, expressed receptors for immune complexes. Macrophages, apparently of host origin, residing in the SEYF-a tumor, also expressed such receptors.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 185060     DOI: 10.1002/eji.1830060810

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  4 in total

Review 1.  Membrane antigens associated with infection, transformation, and tumorigenesis by polyoma virus.

Authors:  I P Witz; G Meyer
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

Review 2.  Fc gamma receptors and cancer.

Authors:  Lydie Cassard; Joël Cohen-Solal; Sophie Camilleri-Broët; Emilie Fournier; Wolf Herman Fridman; Catherine Sautès-Fridman
Journal:  Springer Semin Immunopathol       Date:  2006-11-10

3.  Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity.

Authors:  G R Braslawsky; K Kadow; J Knipe; K McGoff; M Edson; T Kaneko; R S Greenfield
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 4.  FcR may function as a progression factor of nonlymphoid tumors.

Authors:  I P Witz; M Ran
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.